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SS-1  Uric acid metabolism in 
human: Overview 
Naohiko Anzai, Motoshi Ouchi, Naoyuki Otani, 
Promsuk Jutabha
Dept. Pharmacol. Toxicol., Dokkyo Medical Univ. Sch. Med.
Urate (uric acid) is the À nal product of purine metabolism 
in humans owing to the genetic loss of hepatic urate oxidase 
(uricase). Despite its potential advantage as an antioxidant, 
sustained hyperuricemia is associated with gout, renal 
diseases, hypertension and cardiovascular diseases. Serum 
urate level is determined by the interplay between the 
rates of production and elimination. Urate is produced 
mainly in the liver by xanthine oxidase, and two-thirds of 
it is excreted via the kidneys with the remaining one third 
excreted into the gut. Since the kidney plays a dominant 
role in maintaining serum urate levels through its excretion, 
it is important to understand the molecular mechanism 
of renal urate handling. Although molecular identification 
of the urate/anion exchanger URAT1 (SLC22A12) in 2002 
paved the way for successive identiÀ cation of several urate 
transport-related proteins, the entire picture of effective 
renal urate handling in humans has not yet been clariÀ ed. 
Recently, several genome-wide association studies (GWAS) 
have revealed close associations between serum urate levels 
and single nucleotide polymorphisms (SNPs) in at least ten 
genetic loci including eight transporter-related genes. Here, 
we brieÁ y summarize the current progress concerning urate 
handling in human.
SS-3  Hyperuricemia as a 
cardiovascular risk
Takuya Tsuchihashi
Hypertension Center, Steel Memorial Yawata Hospital
It is well known that hyperuricemia is frequently 
accompanied with the lifestyle-related diseases such as 
hypertension, diabetes and metabolic syndrome.  Indeed, 
the prevalence of hyperuricemia deÀ ned as serum uric acid 
(SUA) level > 7.0 mg/dl or on uric acid-lowering therapy 
is 40.6% in males and 8.6% in females among treated 
hypertensive patients in our institution. Hyperuricemia per 
se is reported to be a risk for the incidence of hypertension 
and diabetes. Furthermore, evidence is accumulating 
that hyperuricemia is an independent risk for stroke, 
coronary artery disease, and end-stage renal failure. 
In the treatment of hypertension, combination therapy 
including diuretics is often required to achieve target blood 
pressure (BP) level advocated by the Japanese Society 
of Hypertension Guideline. Considering that salt intake 
in Japan remains high, diuretics are effective in the BP 
control. However, the diuretics-induced increase in SUA 
may offset the cardiovascular risk reduction expected by 
BP-lowering therapy. Although target SUA level for the 
reduction of cardiovascular events awaits future studies, 
the management of hyperuricemia seems important in the 
patients with lifestyle-related diseases.S2SS-2  Extra-renal urate 
underexcretion type hyperuricemia
Kimiyoshi Ichida1,2
1Dept. Pathophysiol., Sch. Pharm., Tokyo Univ. Pharm. & Life Sci., 2Div. Kid 
&Hypertens., Jikei Univ. Sch. Med.
Generally, hyperuricemia has been classified into urate 
“overproduction type” and/or “underexcretion type” based 
solely on renal urate excretion because urate production 
and renal urate excretion are considered to be main 
regulators. ABCG2/BCRP was recently showed to be a high 
capacity urate exporter, the dysfunction of which raises 
gout/hyperuricemia risk. Here I show that decreased extra-
renal urate excretion caused by ABCG2 dysfunction is a 
common mechanism of hyperuricemia. ABCG2 functions 
were estimated by genotype combination of two common 
ABCG2  variants, nonfunctional Q126X and half-functional 
Q141K and clinical parameters, including urinary urate 
excretion and urate clearance/creatinine clearance ratio, 
were examined in male outpatients with hyperuricemia. 
Paradoxically, ABCG2 export dysfunction significantly 
increased urinary urate excretion and risk ratio of urate 
overproduction. In Abcg2 -knockout mice, increased serum 
uric acid levels and renal urate excretion, and decreased 
intestinal urate excretion were observed. Together with high 
ABCG2 expression in extra-renal tissues, the data suggest 
that the “overproduction type” in the current concept of 
hyperuricemia consists of two subtypes,”extra-renal urate 
underexcretion” and genuine “urate overproduction”.
SS-4  The relationship 
between trichlormethiazide-induced 
hyperuricemia and the genotypes of 
uric acid transporters
Tatsuya Yoshihara1, Hiromitsu Imai2, 
Fumie Shiraishi1, Toshiyuki Sasaguri1
1Dept. Clin. Pharmacol., Kyushu Univ., 2Clin. Pharmacol. Center, Oita 
University Hospital
The concentration of serum uric acid (sUA) is controlled 
by several transporters, such as urate transporter-1, 
Sodium phosphate transporter-4 and multidrug resistance-
associated protein-4 (MRP4) etc. expressed in renal tubular 
cells. Thiazide and loop diuretics often cause hyperuricemia. 
These drugs have been reported to inhibit MRP4, 
which excretes uric acid into urine. A single nucleotide 
polymorphism (SNP) in MRP4 (G2269A) dramatically 
reduces MRP4 function and the allele frequency of this SNP 
is markedly high in the Japanese. Therefore, we examined 
whether this SNP inÁ uences the sUA and uric acid clearance 
(CUA) in the treatment of trichlormethiazide (TCM) by 
clinical studies. Our results showed that this SNP does not 
inÁ uence the increase of sUA. However, CUA was tended to 
be decreased in G allele carriers rather than in A/A allele 
carriers after 1 week treatment with TCM but this tendency 
disappeared after 2 weeks. These results suggest that the 
pathways for UA excretion may be different among the 
MRP4 genotypes and alters by the treatment with diuretics. 
In this presentation, we will discuss the involvement of the 
genotypes of transporters in the cause of diuretics-induced 
hyperuricemia.1
